A Blinded, Randomized, Phase I/II Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras Wildtype Subjects with Metastatic Colorectal Cancer.

Trial Profile

A Blinded, Randomized, Phase I/II Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras Wildtype Subjects with Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2013

At a glance

  • Drugs Brivanib alaninate (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2012 Planned number of patients changed from 114 to 133 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top